KNSA
Kiniksa Pharmaceuticals, Ltd.
Biotechnology
Market Cap$4.22B
5Y Perf.+172.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KNSA vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.-20.9%
KNSA vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KNSA | RCUS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $4.22B | $2.50B |
| Revenue (TTM) | $754M | $236M |
| Net Income (TTM) | $73M | $-369M |
| Gross Margin | 39.0% | 90.7% |
| Operating Margin | 12.4% | -168.6% |
| Forward P/E | 41.6x | — |
| Total Debt | $9M | $99M |
| Cash & Equiv. | $166M | $222M |
KNSA vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KNSA
RCUS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | 100 | 272.8 | +172.8% |
| Arcus Biosciences, … (RCUS) | 100 | 79.1 | -20.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KNSA vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KNSA leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Arcus Biosciences, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
KNSA
Kiniksa Pharmaceuticals, Ltd.
The Income Pick
KNSA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.19
- Rev growth 60.1%, EPS growth 225.0%, 3Y rev CAGR 45.5%
- 192.4% 10Y total return vs RCUS's 45.9%
Best for: income & stability and growth exposure
RCUS
Arcus Biosciences, Inc.
The Momentum Pick
RCUS is the clearest fit if your priority is momentum.
- +209.6% vs KNSA's +112.7%
Best for: momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KNSA | 60.1% revenue growth vs RCUS's -4.3% |
| Quality / Margins | KNSA | 9.7% margin vs RCUS's -156.4% |
| Stability / Safety | KNSA | Beta 0.19 vs RCUS's 1.95, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RCUS | +209.6% vs KNSA's +112.7% |
| Efficiency (ROA) | KNSA | 9.9% ROA vs RCUS's -35.3%, ROIC 17.1% vs -64.1% |
KNSA vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
KNSA vs RCUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKNSALAGGINGRCUS
RCUSArcus Biosciences, In…
1leads
KNSAKiniksa Pharmaceutica…
4leads
6 Total Categories
CATEGORYLEADERvs RCUSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KNSA5/6
Valuation MetricsMultiples, price ratios, and targets
RCUS2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KNSA8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
KNSA5/6
Risk & VolatilityBeta, volatility, and downside exposure
KNSA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KNSA leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KNSA is the larger business by revenue, generating $754M annually — 3.2x RCUS's $236M. KNSA is the more profitable business, keeping 9.7% of every revenue dollar as net income compared to RCUS's -156.4%. On growth, KNSA holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KNSAKiniksa Pharmaceu… | RCUSArcus Biosciences… |
|---|---|---|
| RevenueTrailing 12 months | $754M | $236M |
| EBITDAEarnings before interest/tax | $94M | -$391M |
| Net IncomeAfter-tax profit | $73M | -$369M |
| Free Cash FlowCash after capex | $164M | -$489M |
| Gross MarginGross profit ÷ Revenue | +39.0% | +90.7% |
| Operating MarginEBIT ÷ Revenue | +12.4% | -168.6% |
| Net MarginNet income ÷ Revenue | +9.7% | -156.4% |
| FCF MarginFCF ÷ Revenue | +21.8% | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +55.5% | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +145.5% | +10.5% |
KNSA leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
RCUS leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | KNSAKiniksa Pharmaceu… | RCUSArcus Biosciences… |
|---|---|---|
| Market CapShares × price | $4.2B | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $4.1B | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | 75.91x | -7.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 41.56x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 51.65x | — |
| Price / SalesMarket cap ÷ Revenue | 6.23x | 10.11x |
| Price / BookPrice ÷ Book value/share | 7.92x | 4.22x |
| Price / FCFMarket cap ÷ FCF | 166.24x | — |
RCUS leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
KNSA leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
KNSA delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-69 for RCUS. KNSA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), KNSA scores 6/9 vs RCUS's 0/9, reflecting solid financial health.
| Metric | KNSAKiniksa Pharmaceu… | RCUSArcus Biosciences… |
|---|---|---|
| ROE (TTM)Return on equity | +13.3% | -69.0% |
| ROA (TTM)Return on assets | +9.9% | -35.3% |
| ROICReturn on invested capital | +17.1% | -64.1% |
| ROCEReturn on capital employed | +14.0% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 0 |
| Debt / EquityFinancial leverage | 0.02x | 0.16x |
| Net DebtTotal debt minus cash | -$156M | -$123M |
| Cash & Equiv.Liquid assets | $166M | $222M |
| Total DebtShort + long-term debt | $9M | $99M |
| Interest CoverageEBIT ÷ Interest expense | — | -13.38x |
KNSA leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
KNSA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KNSA five years ago would be worth $38,913 today (with dividends reinvested), compared to $8,143 for RCUS. Over the past 12 months, RCUS leads with a +209.6% total return vs KNSA's +112.7%. The 3-year compound annual growth rate (CAGR) favors KNSA at 63.0% vs RCUS's 7.7% — a key indicator of consistent wealth creation.
| Metric | KNSAKiniksa Pharmaceu… | RCUSArcus Biosciences… |
|---|---|---|
| YTD ReturnYear-to-date | +35.5% | +6.5% |
| 1-Year ReturnPast 12 months | +112.7% | +209.6% |
| 3-Year ReturnCumulative with dividends | +333.3% | +24.9% |
| 5-Year ReturnCumulative with dividends | +289.1% | -18.6% |
| 10-Year ReturnCumulative with dividends | +192.4% | +45.9% |
| CAGR (3Y)Annualised 3-year return | +63.0% | +7.7% |
KNSA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
KNSA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KNSA is the less volatile stock with a 0.19 beta — it tends to amplify market swings less than RCUS's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KNSA currently trades 97.7% from its 52-week high vs RCUS's 86.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KNSAKiniksa Pharmaceu… | RCUSArcus Biosciences… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.19x | 1.95x |
| 52-Week HighHighest price in past year | $58.25 | $28.72 |
| 52-Week LowLowest price in past year | $24.85 | $7.06 |
| % of 52W HighCurrent price vs 52-week peak | +97.7% | +86.3% |
| RSI (14)Momentum oscillator 0–100 | 74.9 | 60.5 |
| Avg Volume (50D)Average daily shares traded | 708K | 1.2M |
KNSA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KNSA as "Buy" and RCUS as "Buy". Consensus price targets imply 21.0% upside for RCUS (target: $30) vs 12.4% for KNSA (target: $64).
| Metric | KNSAKiniksa Pharmaceu… | RCUSArcus Biosciences… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $64.00 | $30.00 |
| # AnalystsCovering analysts | 11 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KNSA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RCUS leads in 1 (Valuation Metrics).
Best OverallKiniksa Pharmaceuticals, Lt… (KNSA)Leads 4 of 6 categories
Loading custom metrics...
KNSA vs RCUS: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is KNSA or RCUS a better buy right now?
For growth investors, Kiniksa Pharmaceuticals, Ltd.
(KNSA) is the stronger pick with 60. 1% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Kiniksa Pharmaceuticals, Ltd. (KNSA) offers the better valuation at 75. 9x trailing P/E (41. 6x forward), making it the more compelling value choice. Analysts rate Kiniksa Pharmaceuticals, Ltd. (KNSA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KNSA or RCUS?
Over the past 5 years, Kiniksa Pharmaceuticals, Ltd.
(KNSA) delivered a total return of +289. 1%, compared to -18. 6% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: KNSA returned +192. 4% versus RCUS's +45. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KNSA or RCUS?
By beta (market sensitivity over 5 years), Kiniksa Pharmaceuticals, Ltd.
(KNSA) is the lower-risk stock at 0. 19β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 918% more volatile than KNSA relative to the S&P 500. On balance sheet safety, Kiniksa Pharmaceuticals, Ltd. (KNSA) carries a lower debt/equity ratio of 2% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KNSA or RCUS?
By revenue growth (latest reported year), Kiniksa Pharmaceuticals, Ltd.
(KNSA) is pulling ahead at 60. 1% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Kiniksa Pharmaceuticals, Ltd. grew EPS 225. 0% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, KNSA leads at 45. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KNSA or RCUS?
Kiniksa Pharmaceuticals, Ltd.
(KNSA) is the more profitable company, earning 8. 7% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 8. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KNSA leads at 11. 4% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is KNSA or RCUS more undervalued right now?
Analyst consensus price targets imply the most upside for RCUS: 21.
0% to $30. 00.
07Which pays a better dividend — KNSA or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is KNSA or RCUS better for a retirement portfolio?
For long-horizon retirement investors, Kiniksa Pharmaceuticals, Ltd.
(KNSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19), +192. 4% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KNSA: +192. 4%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between KNSA and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KNSA is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(KNSA: 55.5% · RCUS: -39.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.